Vivus Inc. (NASDAQ:VVUS) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, July 28th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.
Vivus (NASDAQ:VVUS) last posted its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.09. The business had revenue of $15.32 million for the quarter, compared to analyst estimates of $17.97 million. During the same period last year, the business earned ($0.15) EPS. Vivus’s revenue was down 52.4% compared to the same quarter last year. On average, analysts expect Vivus to post $-0.82 EPS for the current fiscal year and $-0.56 EPS for the next fiscal year.
Several equities research analysts have recently commented on the company. WallachBeth Capital set a $2.80 price target on Vivus and gave the stock a “buy” rating in a research note on Monday. Zacks Investment Research raised Vivus from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Tuesday, July 12th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Vivus in a research note on Wednesday, May 4th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Vivus has a consensus rating of “Hold” and an average target price of $1.68.
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
